Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Madrigal Pharmaceuticals has demonstrated significant clinical efficacy with its drug Rezdiffra, successfully shifting approximately two-thirds of patients with Compensated Sphincter of High Risk (CSPH) to lower risk scores, which underscores its therapeutic potential in treating metabolic dysfunction-associated steatohepatitis (MASH). The company's strong real-world adherence and persistence metrics, combined with notable improvements in Health Related Quality of Life (HRQL) for patients with varying stages of MASH, further validate the medication’s long-term benefits and attractiveness to both prescribers and patients. As a result, Madrigal Pharmaceuticals is projecting an optimistic revenue estimate of $7.1 billion by 2035, highlighting the company’s potential for future growth as it expands its patient base.

Madrigal Pharmaceuticals faces several fundamental challenges that contribute to a negative outlook on its stock, primarily stemming from anticipated lower peak sales due to competition and potential lack of support from healthcare prescribers and third-party payers. Additionally, revenue projections suggest a decline in 1Q26, further exacerbated by a planned increase in gross-to-net adjustments starting in January, highlighting the company's vulnerability to market dynamics and regulatory outcomes. Key risks include the possibility of failing to secure necessary FDA and EMA approvals, encountering significant delays or failures in clinical trials, and facing unforeseen competitive pressures, all of which could hinder its operational and financial stability.